# DESCRIPTION

## FIELD

- introduce TIGIT antibodies for cancer treatment

## BACKGROUND

- describe TIGIT protein structure and function
- summarize TIGIT expression and role in cancer and viral infections
- discuss limitations of current cancer treatments

## SUMMARY OF THE INVENTION

- introduce anti-TIGIT antibodies for cancer treatment
- describe antibody structure and binding properties
- outline method of cancer treatment using anti-TIGIT and anti-PD1 antibodies
- specify various embodiments of the method

## DETAILED DESCRIPTION

### Definitions

- define conservative amino acid substitutions
- define technical and scientific terms
- define singular and plural forms of words
- define "or" and "and/or"
- define "comprise" and variations
- define "TIGIT" and its isoforms
- define "administration", "antibody", and related terms

### Anti-TIGIT Antibodies

- introduce anti-TIGIT antibodies with desirable pharmacokinetic characteristics

### Anti-PD1 Antibodies

- introduce anti-PD1 antibodies with specific heavy and light chain variable regions

### Further Alteration of the Framework of Fc Region

- alter Fc region to change effector functions
- modify glycosylation patterns to increase ADCC
- reduce ADCC by modifying IgG4 Fc region

### Antibody Production

- produce anti-TIGIT antibodies by recombinant expression
- encode variable region sequences of anti-TIGIT antibodies
- use expression vectors and host cells for production

### Methods of Detection and Diagnosis

- detect TIGIT in biological samples using anti-TIGIT antibodies

### Methods of Treatment

- treat cancer with anti-TIGIT antibodies
- administer antibodies by various routes and schedules
- use combination therapy with other therapeutic agents

### Pharmaceutical Compositions and Formulations

- formulate anti-TIGIT antibody with carriers and excipients

### Pharmaceutical Compositions and Kits

- prepare compositions with anti-TIGIT antibody and excipients

## EXAMPLE

### Example 1: Generation of Anti-TIGIT Monoclonal Antibody

- generate monoclonal antibodies using hybridoma fusion technology
- select antibodies with high binding activity in ELISA and FACS
- characterize antibodies by functional assays

### Example 2: Cloning and Sequence Analysis of TIGIT Antibodies

- clone and sequence analyze murine mAbs to determine Vh and Vk regions

### Example 3: Affinity Determination of Purified Murine Anti-TIGIT Antibodies by SPR

- determine binding kinetics of purified murine antibodies by SPR

### Example 4: Humanization of the Murine Anti-Human TIGIT mAb mu1217

- humanize mu1217 by CDR-grafting and framework mutations
- engineer humanized antibodies with improved molecular and biophysical properties

### Example 5: Binding Activities of Different Versions of 1217 to Native TIGIT

- evaluate binding activity of anti-TIGIT antibodies to native TIGIT on living cells

### Example 6: Anti-TIGIT Antibodies Block the Interactions of TIGIT with its Ligands PVR and PVR-L2

- determine blockade of TIGIT-ligand interaction by anti-TIGIT antibodies

### Example 7: Activation of CMV-Specific Human T Cells by Anti-TIGIT Antibodies

- assess functional activity of TIGIT antibodies using CMV-specific human T cells

### Example 8: Anti-TIGIT Antibodies Enhanced NK Cell-Mediated Cytotoxicity

- determine enhancement of NK cell-mediated cytotoxicity by anti-TIGIT antibodies

### Example 9: Anti-TIGIT Antibodies can Reduce the Surface Expression of TIGIT Receptor Via FcγR-Mediated Trogocytosis

- introduce trogocytosis phenomenon
- describe antibody-induced trogocytosis via FcγRs
- hypothesize trogocytosis of TIGIT receptor by hu1217-2-2/IgG1
- design experiment to test trogocytosis hypothesis
- perform experiment with Jurkat/TIGIT cells and HEK cells
- analyze surface expression of TIGIT receptor
- show results of trogocytosis experiment
- discuss implications of trogocytosis on TIGIT receptor signaling
- conclude trogocytosis of TIGIT receptor by hu1217-2-2/IgG1
- introduce lung cancer
- motivate treatment of NSCLC
- describe trial of hu1217-2-2 with BGB-A317 in NSCLC
- introduce nasopharyngeal carcinoma
- motivate treatment of NPC
- describe trial of hu1217-2-2 with BGB-A317 in NPC
- introduce esophageal cancer and cervical cancer
- introduce cervical cancer
- motivate anti-TIGIT antibodies
- describe trial design for hu1217-2-2 and BGB-A317
- present results of hu1217-2-2 and BGB-A317 combination therapy
- describe BAT1706 and its efficacy
- outline trial design for hu1217-2-2, BGB-A317, and BAT1706 combination therapy

